Blockchain Registration Transaction Record

TransCode's TTX-MC138 Poster to Debut at ESMO 2026

TransCode Therapeutics (NASDAQ: RNAZ) to present TTX-MC138 Phase 1a update at ESMO 2026. TTX-MC138 targets miR-10b in advanced cancers.

TransCode's TTX-MC138 Poster to Debut at ESMO 2026

The upcoming ESMO presentation underscores the progress of TTX-MC138, a first-in-class RNA therapeutic targeting miR-10b, a key driver of metastasis. Positive Phase 1a data could validate TransCode's approach to treating metastatic cancers, potentially attracting investment and partnerships. For patients with advanced solid tumors, this represents a novel strategy that may address unmet needs. The news also highlights the role of communications platforms like NetworkNewsWire in disseminating critical developments to investors and the public.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x21b6395ddcc079fcfac2749cef23e8e5750a2c0e01508decb520ad0cbf387939
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintdash7ice-2d13335a795a00bb5391ec297db7f7ef